Literature DB >> 17994181

The treatment of cervical dystonia with botulinum toxins.

C L Comella1.   

Abstract

Botulinum neurotoxin (BoNT) treatment has been used extensively for the treatment of cervical dystonia. There are three established brands and two serotypes of BoNT commercially available in most of the world, and several additional brands are available in selected geographic regions. In most controlled studies, there is significant improvement following treatment for head posture, pain and disability. The common side effects of treatment include dysphagia, dry mouth, and neck weakness. Each brand and serotype is pharmacologically distinct. The dosing of each type differs, and no simple dose equivalency has been established. With repeated treatment, the development of immunoresistance is observed in a percentage of patients. However, it is likely that each brand and serotype may differ in immunogenic potential and occurrence of secondary unresponsiveness, an issue that is currently under active investigation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17994181     DOI: 10.1007/s00702-007-0831-4

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  30 in total

1.  Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.

Authors:  D Ranoux; C Gury; J Fondarai; J L Mas; M Zuber
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 2.  Clinical comparability of marketed formulations of botulinum toxin.

Authors:  Cristina Sampaio; João Costa; Joaquim J Ferreira
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

3.  Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A.

Authors:  A Brashear; K Bergan; J Wojcieszek; E R Siemers; W Ambrosius
Journal:  Mov Disord       Date:  2000-01       Impact factor: 10.338

4.  Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.

Authors:  Albert Marchetti; Raf Magar; Leslie Findley; Jan P Larsen; Zvezdan Pirtosek; Evzen Růzicka; Evzen Råuzizka; Robert Jech; Jaroslaw Sławek; Fayyaz Ahmed
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

5.  Idiopathic cervical dystonia: clinical characteristics.

Authors:  J Chan; M F Brin; S Fahn
Journal:  Mov Disord       Date:  1991       Impact factor: 10.338

6.  Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients.

Authors:  I T Lorentz; S S Subramaniam; C Yiannikas
Journal:  Mov Disord       Date:  1991       Impact factor: 10.338

7.  Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.

Authors:  M F Brin; M F Lew; C H Adler; C L Comella; S A Factor; J Jankovic; C O'Brien; J J Murray; J D Wallace; A Willmer-Hulme; M Koller
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

8.  Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.

Authors:  A Brashear; M F Lew; D D Dykstra; C L Comella; S A Factor; R L Rodnitzky; R Trosch; C Singer; M F Brin; J J Murray; J D Wallace; A Willmer-Hulme; M Koller
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

9.  Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Authors:  Daniel Truong; Drake D Duane; Joseph Jankovic; Carlos Singer; Lauren C Seeberger; Cynthia L Comella; Mark F Lew; Robert L Rodnitzky; Fabio O Danisi; James P Sutton; P David Charles; Robert A Hauser; Geoffrey L Sheean
Journal:  Mov Disord       Date:  2005-07       Impact factor: 10.338

10.  Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis.

Authors:  D J Gelb; D H Lowenstein; M J Aminoff
Journal:  Neurology       Date:  1989-01       Impact factor: 9.910

View more
  6 in total

Review 1.  Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

2.  Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia.

Authors:  Andre C Felicio; Clecio Godeiro-Junior; Patricia de Carvalho Aguiar; Vanderci Borges; Sonia M A Silva; Henrique B Ferraz
Journal:  Neurol Sci       Date:  2009-05-26       Impact factor: 3.307

3.  Treatment of focal dystonia.

Authors:  Amit Batla; Maria Stamelou; Kailash P Bhatia
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.598

Review 4.  Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.

Authors:  Sheng Chen
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

5.  Intramuscular Neural Distribution of the Serratus Anterior Muscle: Regarding Botulinum Neurotoxin Injection for Treating Myofascial Pain Syndrome.

Authors:  Kyu-Ho Yi; Ji-Hyun Lee; Hee-Jin Kim
Journal:  Toxins (Basel)       Date:  2022-04-11       Impact factor: 5.075

6.  Injection into the Longus Colli Muscle via the Thyroid Gland.

Authors:  Małgorzata Tyślerowicz; Wolfgang H Jost
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-12-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.